VivoSeq
Oncology

Benign Muscle Neoplasm

5

Pipeline Programs

0

Active Trials

2

Companies Involved

Benign Muscle Neoplasm is an early-stage landscape with 5 programs across 2 companies. The most active players are Pfizer, Retrophin. 4 therapies are approved.

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

N/A

Attrition Rate

N/A

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)